Compare STRIDES PHARMA SCIENCE with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs PANACEA BIOTECH - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE PANACEA BIOTECH STRIDES PHARMA SCIENCE/
PANACEA BIOTECH
 
P/E (TTM) x 16.1 12.6 127.9% View Chart
P/BV x 1.0 3.0 31.5% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   PANACEA BIOTECH
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
PANACEA BIOTECH
Mar-18
STRIDES PHARMA SCIENCE/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,147364 315.1%   
Low Rs642129 497.3%   
Sales per share (Unadj.) Rs317.296.8 327.8%  
Earnings per share (Unadj.) Rs7.8-12.4 -63.2%  
Cash flow per share (Unadj.) Rs25.1-2.9 -878.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.350.4 544.2%  
Shares outstanding (eoy) m89.5061.25 146.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.5 110.7%   
Avg P/E ratio x114.0-19.9 -573.9%  
P/CF ratio (eoy) x35.7-86.4 -41.3%  
Price / Book Value ratio x3.34.9 66.7%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,05815,101 530.1%   
No. of employees `0002.52.5 101.6%   
Total wages/salary Rs m4,3411,516 286.3%   
Avg. sales/employee Rs Th11,325.82,401.9 471.5%   
Avg. wages/employee Rs Th1,731.4614.2 281.9%   
Avg. net profit/employee Rs Th280.1-307.9 -90.9%   
INCOME DATA
Net Sales Rs m28,3945,928 479.0%  
Other income Rs m94182 1,142.9%   
Total revenues Rs m29,3346,010 488.1%   
Gross profit Rs m3,965845 469.1%  
Depreciation Rs m1,540585 263.2%   
Interest Rs m1,9621,006 195.1%   
Profit before tax Rs m1,403-664 -211.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1682 -8,000.0%   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m9799 98.7%   
Profit after tax Rs m702-760 -92.4%  
Gross profit margin %14.014.3 97.9%  
Effective tax rate %6.9-14.9 -46.7%   
Net profit margin %2.5-12.8 -19.3%  
BALANCE SHEET DATA
Current assets Rs m24,8365,603 443.2%   
Current liabilities Rs m18,9936,910 274.9%   
Net working cap to sales %20.6-22.0 -93.4%  
Current ratio x1.30.8 161.3%  
Inventory Days Days71206 34.5%  
Debtors Days Days11384 135.4%  
Net fixed assets Rs m34,2899,941 344.9%   
Share capital Rs m89561 1,460.0%   
"Free" reserves Rs m23,6513,026 781.7%   
Net worth Rs m24,5463,087 795.2%   
Long term debt Rs m15,5135,707 271.8%   
Total assets Rs m65,43716,076 407.1%  
Interest coverage x1.70.3 503.9%   
Debt to equity ratio x0.61.8 34.2%  
Sales to assets ratio x0.40.4 117.7%   
Return on assets %4.11.5 266.3%  
Return on equity %2.9-24.6 -11.6%  
Return on capital %6.93.9 176.0%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m15,6971,600 981.1%   
Fx outflow Rs m7351,131 65.0%   
Net fx Rs m14,962469 3,192.9%   
CASH FLOW
From Operations Rs m1,8711,180 158.5%  
From Investments Rs m5,826553 1,053.7%  
From Financial Activity Rs m-10,157-1,644 618.0%  
Net Cashflow Rs m-2,61590 -2,915.2%  

Share Holding

Indian Promoters % 27.7 74.5 37.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.6 6,300.0%  
FIIs % 8.6 1.3 661.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 23.6 109.7%  
Shareholders   56,241 10,259 548.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 13, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS